Abstract
The following valpromide (VPD) analogues were synthesized and their structure-pharmacokinetic relationships explored: 3-ethyl pentanamide (EPD), methylneopentylacetamide (MND), 1-methyl cyclohexanecarboxamide (MCD), cycloheptanecarboxamide (CHD), and t-butylacetamide (TBD). Two aliphatic (EPD and MND) and two cyclic amides (MCD and CHD) underwent complete or partial conversion to their corresponding acids. The only amide found in this study to be “stable” to the amide-acid biotransformation was TBD. It also had the lowest clearance and the longest half-life and mean residence time. Unlike the other investigated amides, TBD contained two substitutions of two methyl moieties at the β position of its chemical structure. A “stable” valpromide analogue must have either two substitutions at the β position, such as in the case of TBD, or a substitution in the α and β positions, such as in the case of the VPD isomer valnoctamide (VCD). This paper discusses the antiepileptic potential of stable VPD analogues which may be more potent and less teratogenic than their biotransformed isomers.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
F. E. Dreifuss. Valproate-toxicity. In R. H. Levy, F. E. Dreifuss, R. H. Mattson, B. S. Meldrum, and J. K. Perry (eds.), Antiepileptic Drugs, 3rd ed., Raven Press, New York, 1989, pp. 643–651.
R. J. Porter. Antiepileptic drugs, efficacy and inadequacy. In B. S. Meldrum and R. J. Porter (eds.), New Anticonvulsant Drugs, John Libbey, London, 1986, pp. 3–15.
G. L. Plaa. General principles—toxicology In R. H. Levy, F. E. Dreifuss, R. H. Mattson, B. S. Meldrum, and J. K. Penry (eds.), Antiepileptic Drugs, 3rd ed., Raven Press, New York, 1989, pp. 49–58.
P. E. Keane, J. Simiand, E. Mendes, V. Santucci, and M. Morre. The effects of analogues of valproic acid on seizures induced by pentylenetetrazol and GABA content in brain of mice. Neuropharmacology 22:875–879 (1983).
W. Loscher and H. Nau. Pharmacological evaluation of various metabolites and analogues of valproic acid. Neuropharmacology 24:427–435 (1985).
F. S. Abbott and A. A. Acheampong. Quantitative structure-anticonvulsant activity relationships of valproic acid, related carboxylic acids and tetrazoles. Neuropharmacology 27:287–294 (1988).
A. Haj-Yehia and M. Bialer. Structure-pharmacokinetic relationships in a series of valpromide derivatives with antiepileptic activity. Pharm. Res. 6:682–689 (1989).
A. Haj-Yehia and M. Bialer. Structure-pharmacokinetic relationships in a series of short fatty acid amides that possess anticonvulsant activity. J. Pharm. Sci. 79:719–724 (1990).
M. Bialer. Clinical pharmacology of valpromide. Clin. Pharmacokinet. 20:114–122 (1991).
A. Haj-Yehia and M. Bialer. Pharmacokinetics of a valpromide isomer, valnoctamide, in dogs. J. Pharm. Sci. 77:831–854 (1988).
M. Bialer, A. Haj-Yehia, N. Barzaghi, F. Pisani, and E. Perucca. Pharmacokinetics of valpromide isomer, valnoctamide in healthy subjects. Eur. J. Clin. Pharmacol. 38:289–291 (1990).
M. Bialer, M. Friedman, and J. Dubrovsky. A rapid GLC assay for monitoring valproic acid and valpromide in plasma. J. Pharm. Sci. 73:991–993 (1984).
M. Bialer and B. Hoch. Rapid gas chromatographic assay for monitoring valnoctamide in plasma. J. Chromatogr. Biomed. Appl. 337:408–411 (1985).
M. Gibaldi and D. Perrier. Pharmacokinetics, 2nd ed., Marcel Dekker, New York, 1982, pp. 445–449.
L. Z. Benet and R. L. Galeazzi. Non-compartmental determination of steady-state volume of distribution. J. Pharm. Sci. 68:1071–1074 (1979).
K. Yamaoka, T. Nakagawa, and T. Uno. Statistical moments in pharmacokinetics. J. Pharmacokinet. Biopharm. 6:547–558 (1977).
K. Yamaoka. Methods for Pharmacokinetic Analysis for Personal Computer, 2nd ed., Nanko-D, Tokyo, 1986, pp. 145–175.
S. A. Kaplan, M. L. Jack, S. Cotler, and K. Alexander. Utilization of area under the curve to elucidate the disposition of an extensively biotransformed drug. J. Pharmacokinet. Biopharm. 1:201–212 (1973).
M. Rowland and T. Tozer. Clin. Pharmacokinet., 2nd ed., Lea and Febiger, Philadelphia, 1989, pp. 347–359.
M. Rowland and T. Tozer. Clin. Pharmacokinet., 2nd ed., Lea and Febiger, Philadelphia, 1989, pp. 151–152.
K. S. Pang. A review of metabolite kinetics. J. Pharmacokinet. Biopharm. 13:633–663 (1985).
M. Gibaldi and D. Perrier. Pharmacokinetics, 2nd ed., Marcel Dekker, New York, 1982, pp. 327–330.
P. L. Altman and D. S. Dittmer. Biological Pata Book, 2nd ed., Federation of American Societies of Experimental Biology, Bethesda, MD, 1974, Vol. III, pp. 1702–1710.
H. Nau and A. G. Hendrickx. Valproic acid teratogenesis. ISI Atlas Sci. Pharmacol. 52–56 (1987).
F. E. Dreifuss, N. Santilli, D. H. Langer, K. P. Sweeney, K. A. Moline, and K. B. Menander. Valproic acid hepatic fatalities: A retrospective review. Neurology 37:379–385 (1987).
J. W. Kesterson, G. R. Granneman, and J. M. Machinist. The hepatotoxicity of valproic acid and its metabolites in rats. I. Toxicologic, biochemical and histopathalogical studies. Hepatology 4:1143–1152 (1984).
E. Kingsly, P. D. Gray, K. G. Tolman, and R. Tweedale. The toxicity of the metabolites of sodium valproate in cultured hepatocytes. J. Clin. Pharmacol. 23:178–185 (1983).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Haj-Yehia, A., Hadad, S. & Bialer, M. Pharmacokinetic Analysis of the Structural Requirements for Forming “Stable” Analogues of Valpromide. Pharm Res 9, 1058–1063 (1992). https://doi.org/10.1023/A:1015862613315
Issue Date:
DOI: https://doi.org/10.1023/A:1015862613315